Your web browser is out of date.
For your security and improved experience online, please update your browser.
Chronic kidney disease (CKD) is a potentially devastating condition in adults with type 2 diabetes.1 However, timely diagnosis through regular screening and early treatment may slow the progression of the condition.2
NICE has recently recommended use of certain sodium-glucose co-transporter 2 (SGLT2) inhibitors in addition to an angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor at an optimised dose in adults with type 2 diabetes and CKD whose albumin:creatinine ratio is more than 30 mg/mmol.3 Meanwhile, the UK Kidney Association recently published guidelines recommending the use of SGLT2 inhibitors in adults with type 2 diabetes and an ACR ≥25 mg/mmol, and suggesting their use in suitable patients with an ACR >3 mg/mmol.4
This live webcast on 15 December 2021 at 13.00 and 19.00 will discuss key points from the recently published NICE recommendations for the management of adults with type 2 diabetes and CKD. The importance of early screening for CKD in adults with type 2 diabetes and the potential impact these updates will have on clinical practice and the prescribing of SGLT2 inhibitors will also be explored.
Introduction and welcome
Recent guideline updates for the management of chronic kidney disease in people with type 2 diabetes: Key points
What impact will the guideline updates have in clinical practice?
Professor of Renal Medicine & Honorary Consultant Nephrologist, Leicester
GP with a Special Interest in Diabetes & Education, Cardiff
National Specialty Advisor, Diabetes, NHS England
Sign up to all DiabetesontheNet journals
This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.